p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population

National Medical Journal of China

Volumn 85, Issue 2, 2005, Pages 76-79

  Zhu, Zhong Zheng ^a   Cong, Wen Ming ^b   Liu, Shu Fang ^b   Dong, Hui ^b   Zhu, Guan Shan ^b   Wu, Meng Chao ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Gene, p53; Genetic polymorphism; Genetic susceptibility; Liver cancer

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ARTICLE; CANCER RISK; CHINESE; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ALLELES; CARCINOMA, HEPATOCELLULAR; CODON; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; POLYMORPHISM, GENETIC;

EID: 15344346612     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 1998, 393: 229-234.
2. Lee JM, Lee YC, Yang SY, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer, 2000, 89: 458-464.
3. Zhang JH, Li Y, Wang R, et al. p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population. Chin J Oncol, 2003, 25: 365-367.
4. Zhang L, Xing DY, He ZG, et al. p53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population. Chin J Med Genet, 2002, 19: 10-13.
5. Leveri M, Gritti C, Rossi L, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett, 2004, 208: 75-79.
6. Anzola M, Cuevas N, Lopez-Martinez M, et al. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett, 2003, 193: 199-205.
7. Yu MW, Yang SY, Chiu YH, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology, 1999, 29: 697-702.
8. Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered, 1994, 44: 266-270.
9. Fang FD. The questions on the genetic analysis in the study of gene polymorphism related to disease. Natl Med J China, 2004, 84: 796-798.
10. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 1999, 19: 1092-1100.
11. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet, 2000, 25: 47-54.
12. Tada M, Furuuchi K, Kaneda M, et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis, 2001, 22: 515-517.
13. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer, 2002, 87: 1013-1018.
14. Monti P, Campomenosi P, Ciribilli Y, et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene, 2003, 22: 5252-5260.
15. Gaiddon C, Lokshin M, Ahn J, et al. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol, 2001, 21: 1874-1887.
16. Moreau F, Matlashewski G. Molecular analysis of different allelic variants of wild-type human p53. Biochem Cell Biol, 1992, 70: 1014-1019.
17. Birgander R, Sjalander A, Rannug A, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis, 1995, 16: 2233-2236.
18. Birgander R, Sjalander A, Zhou Z, et al. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered, 1996, 46: 49-54.